Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,Relief of nasal congestion associated with allergic rhinitis or common cold
Relief of symptoms associated with seasonal or perennial allergic rhinitis,Relief of nasal congestion,Symptomatic relief of upper respiratory tract infections
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.
Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine p H).
Dexbrompheniramine: terminal elimination half-life is approximately 12-25 hours in adults. Pseudophedrine: terminal elimination half-life is about 5-8 hours in adults with normal renal function; it is prolonged in patients with renal impairment.
Desloratadine is metabolized to 3-hydroxydesloratadine via CYP2C8 and CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Dexbrompheniramine is primarily metabolized by CYP3A4 and CYP2D6. Pseudoephedrine is partially metabolized by N-demethylation and oxidative deamination, with about 43-96% excreted unchanged in urine.
Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary.
Dexbrompheniramine and its metabolites are primarily excreted renally (approximately 80-85% of a dose as unchanged drug and metabolites). Pseudophedrine is largely excreted unchanged in urine (70-90%) via glomerular filtration and tubular secretion; the remainder is hepatically metabolized. Biliary/fecal elimination is minimal (<5%).
Desloratadine: 83-87% bound (primarily albumin); pseudoephedrine sulfate: minimal binding, ~20% bound.
Dexbrompheniramine: approximately 90% bound to plasma proteins. Pseudophedrine: negligible protein binding (<10%).
Desloratadine: ~16.8 L/kg (high Vd, extensive tissue distribution); pseudoephedrine sulfate: ~2.6-3.5 L/kg (moderate Vd).
Dexbrompheniramine: Vd is approximately 3-5 L/kg, indicating extensive tissue distribution. Pseudophedrine: Vd is approximately 2.5-3.5 L/kg.
Desloratadine: 76% (oral); pseudoephedrine sulfate: ~100% (extended-release formulation).
Both components are well absorbed orally. Dexbrompheniramine: oral bioavailability is approximately 60-80%. Pseudophedrine: oral bioavailability is about 90-100%.
Contraindicated in GFR < 30 m L/min. For GFR 30-59 m L/min: not recommended due to lack of data. For GFR ≥ 60 m L/min: no adjustment needed.
GFR 30-50 m L/min: extend interval to every 12-24 hours; GFR <30 m L/min: contraindicated due to risk of accumulation.
No specific Child-Pugh based recommendations. Use with caution in severe hepatic impairment; desloratadine clearance reduced.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Not approved for pediatric patients; safety and efficacy not established in children <12 years. For ≥12 years: same as adult.
Not recommended for children under 12 years; for ages 12+: same as adult dosing.
Use with caution due to increased sensitivity, risk of CNS effects, and potential renal impairment. Consider starting at lower doses; avoid in patients with severe renal impairment.
Start at lowest effective dose (e.g., 1 tablet daily) due to increased sensitivity to anticholinergic effects and risk of confusion; monitor for urinary retention and hypertension.
None.
None.
Severe hypertension and/or tachycardia,Cardiovascular disease including ischemic heart disease and arrhythmias,Increased intraocular pressure,Diabetes mellitus,Thyroid dysfunction,Prostatic hypertrophy/urinary retention,Renal impairment,Seizure disorders,Use in elderly patients
Cardiovascular effects: hypertension, palpitations, arrhythmias; use cautiously in cardiovascular disease,CNS stimulation: nervousness, dizziness, insomnia; avoid in severe hypertension or coronary artery disease,Anticholinergic effects: urinary retention, blurred vision; caution in glaucoma or prostatic hypertrophy,Drug interactions: MAO inhibitors, sympathomimetics, antihypertensives
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension,Coronary artery disease,Use of MAO inhibitors within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Hypersensitivity to any component,Severe hypertension or coronary artery disease,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation,Narrow-angle glaucoma,Urinary retention,Severe hepatic or renal impairment
Avoid alcohol as it may increase sedative effects. Limit or avoid caffeine-containing foods/drinks (coffee, tea, soda, chocolate) to reduce risk of nervousness, insomnia, and tachycardia. No specific food interactions with desloratadine; pseudoephedrine is not significantly affected by food.
Avoid high-tyramine foods (e.g., aged cheese, cured meats, fermented products) if taking MAOIs concurrently. Pseudoephedrine's pressor effect may be enhanced by caffeine; limit caffeinated beverages.
Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester; possible uterine vasoconstriction in second/third trimester. Overall, avoid in first trimester; use only if benefit outweighs risk in second/third trimester.
First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine blood flow and cause fetal tachycardia.
Desloratadine: low excretion into breast milk; M/P ratio not established. Pseudoephedrine: small amounts in milk; peak milk concentration at 2-4 hours; M/P ratio 1.7-3.5. May cause irritability or sleep disturbance in infants; reduce breast milk production. Not recommended during breastfeeding.
Probable compatibility (American Academy of Pediatrics rating). Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio ~3.3); may cause irritability and sleep disruption in infants. Dexbrompheniramine may suppress lactation. Consider using alternatives with lower risk.
No pharmacokinetic data in pregnancy; standard dosing not recommended due to risk profile. Use only if clearly needed and under medical supervision.
No specific adjustments recommended. However, decreased gastrointestinal motility and increased plasma volume may alter absorption and distribution. Monitor clinical response.
Desloratadine is a long-acting antihistamine; pseudoephedrine sulfate is a nasal decongestant. The 24-hour formulation provides extended relief. Use with caution in patients with hypertension, hyperthyroidism, or benign prostatic hyperplasia. Avoid in narrow-angle glaucoma. Monitor for insomnia and nervous system stimulation. May cause dry mouth and urinary retention.
Dexbrompheniramine is an alkylamine antihistamine with sedative effects; pseudoephedrine is a sympathomimetic decongestant. Avoid in severe hypertension, coronary artery disease, or MAOI use. Monitor for CNS stimulation (insomnia, nervousness) from pseudoephedrine. Antihistamines may exacerbate urinary retention in BPH or narrow-angle glaucoma. Combination therapy is common in OTC cold products.
Take one tablet daily with a full glass of water; do not crush or chew.,Avoid taking with other sympathomimetic amines (e.g., pseudoephedrine, phenylephrine) to prevent excessive cardiovascular stimulation.,May cause drowsiness; avoid driving or operating heavy machinery until you know how the medication affects you.,Limit caffeine intake to reduce additive stimulant effects.,Do not use if you have severe hypertension, coronary artery disease, or are taking MAOIs currently or within past 14 days.
Take with food or milk to reduce stomach upset.,Avoid alcohol and other CNS depressants due to additive sedation.,Do not crush or chew extended-release formulations.,Discontinue and consult prescriber if palpitations, dizziness, or tremor occur.,Not recommended for children under 6 years without prescriber approval.,Use caution when driving or operating machinery until response is known.
"Ketazolam, a benzodiazepine, can cause central nervous system (CNS) depression. Desloratadine, a nonsedating antihistamine, has a low potential for CNS depression at therapeutic doses. However, when combined with benzodiazepines, the risk of additive CNS depressant effects increases, potentially leading to excessive sedation, dizziness, and impaired psychomotor function. This interaction is particularly relevant in patients with hepatic impairment or those taking higher doses of either drug."
"Paroxetine, a potent inhibitor of CYP2D6, can increase plasma concentrations of desloratadine, which is partially metabolized by CYP2D6. This elevation in desloratadine levels may potentiate its antihistaminic effects and, more rarely, its cardiac adverse effects such as QT prolongation. Although desloratadine has a low propensity for QT prolongation, the additive serotonergic effects are unlikely, but the interaction is primarily pharmacokinetic, leading to increased exposure and potential dose-related adverse events."
"The coadministration of methadyl acetate and desloratadine may lead to additive QT interval prolongation due to their respective cardiac repolarization effects. Methadyl acetate, as a µ-opioid receptor agonist and known QT-prolonging agent, increases the risk of torsade de pointes and other ventricular arrhythmias. Desloratadine, an antihistamine, possesses weak blocking activity of the hERG potassium channel, which can further potentiate the QT prolongation when combined, resulting in increased risk of life-threatening cardiac arrhythmias, especially in patients with pre-existing risk factors."
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Dexbrompheniramine, a first-generation antihistamine with anticholinergic and sedative properties, when co-administered with guanfacine, an alpha-2 adrenergic agonist used for hypertension or ADHD, can result in additive central nervous system depression. This may lead to enhanced sedation, dizziness, impaired cognitive function, and increased risk of falls, particularly in older adults or those with compromised liver function."
"Quazepam, a benzodiazepine, and dexbrompheniramine, a first-generation antihistamine, both exhibit central nervous system (CNS) depressant effects. Their combined use can lead to additive sedation, psychomotor impairment, and respiratory depression, increasing the risk of falls, cognitive dysfunction, and excessive drowsiness. This interaction is particularly concerning in elderly patients or those with compromised respiratory function."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR vs DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, answered by our medical review team.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is a Sympathomimetic that works by Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.. DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is a Sympathomimetic that works by Dexbrompheniramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE depend on the specific clinical indication. These are both Sympathomimetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is: One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.. The standard adult dose of DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is: 1 tablet (each containing dexchlorpheniramine maleate 2 mg/pseudoephedrine sulfate 120 mg) orally every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR and DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE. Pseudoephedrine, a sympathomimetic amine with indirect alpha- and beta-adrenergic agonist activity, may pharmacodynamically antagonize the sedative effects of desloratadine, a second-generation antihistamine. This occurs via pseudoephedrine's central nervous system (CNS) stimulant properties (e.g., norepinephrine release, direct adrenergic receptor activation) opposing desloratadine's CNS depressant activity, which is mediated through histamine H1-receptor blockade. Clinically, this can lead to reduced therapeutic efficacy of desloratadine for sedation or allergy-related sleep disturbances, though desloratadine's low CNS penetration makes this interaction typically mild. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is classified as Category A/B. Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester;. DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE is classified as Category A/B. First trimester: Avoid; limited human data, but theoretical risk of antihistamine-related malformations. Second and third trimesters: Caution; pseudoephedrine may reduce uterine bl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.